Business
CLINUVEL to advance novel pharmaceutical formulations in preclinical program
Next generation sustained-release formulations for a variety of peptidesExecutive summary first biocompatible pharmaceutical formulations progress to preclinical modelsnew sustained-release drug delivery platforms for peptides, melanocortinsaim to predict drug release kinetics from new formulationsliquid formulation allows flexible dosing through adjusting injection volumesperseverance during 10 years of in-house research MELBOURNE, Australia, Sept. 28, 2025 (GLOBE NEWSWIRE) -- CLINUVEL today an
About this update from Clinuvel Pharmaceuticals Limited
[{"type":"image","alt":"Clinuvel Pharmaceuticals Limited","displaySize":"","headline":null,"caption":"Clinuvel Pharmaceuticals Limited","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":157,"url":"https://media.zenfs.com/en/globenewswire.com/6397a3f79f4dc9eb1683148adb10fab8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/IZGfbstHkppwPJkoYvH5dQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/6397a3f79f4dc9eb1683148adb10fab8","width":300,"height":157}},"lazy":false},{"type":"text","content":"Next generation sustained-release formulations for a variety of peptides","length":72,"tagName":"p"},{"type":"text","content":"Executive summary","length":17,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"first biocompatible pharmaceutical formulations progress to preclinical models","length":78,"tagName":"p"}]},{"val":[{"type":"text","content":"new sustained-release drug delivery platforms for peptides, melanocortins","length":73,"tagName":"p"}]},{"val":[{"type":"text","content":"aim to predict drug release kinetics from new formulations","length":58,"tagName":"p"}]},{"val":[{"type":"text","content":"liquid formulation allows flexible dosing through adjusting injection volumes","length":77,"tagName":"p"}]},{"val":[{"type":"text","content":"perseverance during 10 years of in-house research","length":49,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":335,"olType":false},{"type":"text","content":"MELBOURNE, Australia, Sept. 28, 2025 (GLOBE NEWSWIRE) -- CLINUVEL today announced that it is advancing new sustained-release liquid drug formulations in a preclinical program evaluating various drug release profiles. A decade of investment in fundamental research & development in CLINUVEL’s fully-owned Singaporean laboratories (VALLAURIX) has provided positive, consistent results demonstrating the potential for depot formulations to extend the duration of release of peptide drugs.","length":489,"tagName":"p"},{"type":"text","content":"Investment in novel drug delivery systems","length":41,"tagName":"p"},{"type":"text","content":"CLINUVEL’s formulation development has sought to lengthen the duration of time that peptides are detectable in blood levels and arrive at predictable kinetics – optimising patient exposure to active pharmaceutical ingredients...